Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis

Documenti analoghi

• Single‐center experience with bimekizumab in psoriasis patients with previous exposure to interleukin‐17 inhibitors
  di: Ioannis‐Alexios Koumprentziotis, et al.
  Pubblicazione: (2024)
• Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic‐Naïve and Biologic‐Experienced Patients: Results From a Real‐World, Retrospective Study
  di: Ioannis‐Alexios Koumprentziotis, et al.
  Pubblicazione: (2025)
• Switching within the class of IL‐23 inhibitors for the treatment of psoriasis: A systematic review
  di: Ioannis‐Alexios Koumprentziotis, et al.
  Pubblicazione: (2025)
• Risk of second primary cancers in patients with Merkel cell carcinoma: A systematic review and meta‐analysis
  di: Ioannis‐Alexios Koumprentziotis, et al.
  Pubblicazione: (2025)
• Targeting IL ‐23 in Generalized Pustular Psoriasis: Clinical Success With Guselkumab in an Elderly Patient With Comorbidities
  di: Christina Silaidi, et al.
  Pubblicazione: (2025)